Retrospective cohort study examines CAD impact on early MACE risk in liver transplant candidates, suggesting further exploration is needed.
Cardiovascular disease (CVD) has increased among liver transplant candidates and is the leading cause of early mortality (<1 year) post-transplant. Coronary computed tomography angiography (CCTA) has been increasingly utilized for pre-liver transplant CVD risk stratification; however, no study to date has demonstrated that coronary artery disease (CAD) diagnosed on pre-liver transplant CCTA is associated with early (<1 year) major adverse cardiac events (MACE). To investigate the association between CAD on pre-transplant CCTA and early post-liver transplant MACE we performed a single center, retrospective cohort study of adult liver transplant recipients who completed a CCTA during transplant evaluation from July 2018 to January 2024. Overall, 438 patients underwent CCTA with 276 undergoing liver transplantation. One-year post-transplant MACE-free survival was higher for those without CAD compared to those with any CAD (91.5% [85.6-97.7] vs. 80.6% [75.1-86.6], p = 0.04). However, this association did not persist when adjusting for age, sex, and diabetes (Adjusted HR 1.97, 95% CI: 0.84, 4.58). Our study demonstrates that CAD on pre-liver transplant CCTA increases the risk of early post-transplant MACE; however, further investigation is needed to confirm if the increase is due to CAD or underlying risk factors.
No takes yet. Share an insight, caveat, or question.
Hughes et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: